| abstract |
(57) [Summary]nNovel non-peptide GLP-1 agonists, pharmaceutical compositions comprising them, use of non-peptide GLP-1 agonists for the manufacture of pharmaceutical compositions, and diseases and conditions where activation of the human GLP-1 receptor is useful, In particular, a method for the treatment and / or prevention of metabolic diseases such as IGT, type 1 diabetes, type 2 diabetes and obesity. |